Management considerations for childhood-onset systemic lupus erythematosus patients and implications on therapy

Expert Rev Clin Immunol. 2016;12(3):301-13. doi: 10.1586/1744666X.2016.1123621. Epub 2015 Dec 15.

Abstract

Childhood-onset systemic lupus erythematosus (cSLE) is a chronic inflammatory and autoimmune disease that may involve various organs and systems. This narrative review focuses on the recent evidence relating to cSLE management. The general management considerations of cSLE patients require the use of validated classification criteria, disease and health-related quality of life tools evaluation, as well as assessments of lupus nephritis biomarkers and cSLE quality indicators. The drug treatment for cSLE patients includes general supportive care and immunosuppressive therapy. Important implications on cSLE therapy are also updated such as infection, vaccination, infertility, pregnancy, contraception, dyslipidemia, physical activity, cancer, bone health, drug pharmacokinetics, adherence, academic outcomes, transition to adult care and cumulative organ damage.

Keywords: Childhood-onset systemic lupus erythematosus; cancer; dyslipidemia; exercise; fertility; immunosuppressive; infection; osteoporosis; vaccination; vitamin D.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Age of Onset
  • Animals
  • Child
  • Disease Management
  • Female
  • Health Planning Support
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / epidemiology*
  • Patient Compliance
  • Pregnancy

Substances

  • Immunosuppressive Agents